EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBITLicense, Supply and Distribution Agreement • February 10th, 2020 • Elite Pharmaceuticals Inc /Nv/ • Pharmaceutical preparations • Delaware
THIS LICENSE, SUPPLY AND DISTRIBUTION AGREEMENT is made as of March 6, 2019 (the “Effective Date”), by and between ELITE PHARMACEUTICALS, INC. a Nevada corporation and ELITE LABORATORIES, INC., Delaware corporation located at 165 Ludlow Avenue, Northvale, New Jersey 07647 (collectively, “ELITE”), and LANNETT COMPANY, INC., USA, a Delaware corporation located at 9000 State Road, Philadelphia, PA 19136 and/or its Affiliates (“LANNETT”).
ASSET PURCHASE AGREEMENT BY AND BETWEEN Elite Pharmaceuticals, Inc. AND NOSTRUM LABORATORIES INC. DATED AS OF November 13, 2019 This document is not intended to create, nor will it be deemed to create, a legally binding or enforceable offer or...Asset Purchase Agreement • February 10th, 2020 • Elite Pharmaceuticals Inc /Nv/ • Pharmaceutical preparations • New York
This Asset Purchase Agreement (this “Agreement”), dated as of November 13, 2019, is entered into by and between Elite Pharmaceuticals, Inc., a Nevada corporation (“Seller”), and Nostrum Laboratories Inc., a New Jersey, USA corporation (“Buyer”). Seller and Buyer shall be referred to herein from time to time collectively as the “Parties” and individually as a “Party”. Capitalized words have the definitions set forth in Annex A.
EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IN PUBLICLY DISCLOSED. FIRST AMENDMENT TO THE LICENSE, SUPPLY AND DISTRIBUTION AGREEMENT...License, Supply and Distribution Agreement • February 10th, 2020 • Elite Pharmaceuticals Inc /Nv/ • Pharmaceutical preparations
This Amendment, dated as of August 1, 2018 (the “Amendment”), by and between Elite Laboratories, Inc. (a subsidiary of Elite Pharmaceuticals, Inc.), a corporation organized under the laws of the State of Delaware, with offices at 165 Ludlow Avenue, Northvale, New Jersey (“Elite”) and Glenmark Pharmaceuticals Inc. USA, a Delaware corporation located at 750 Corporate Drive, Mahwah, New Jersey 07430 (“Glenmark”) relating to that License, Supply and Distribution Agreement Between Elite Laboratories, Inc. (a subsidiary of Elite Pharmaceuticals, Inc.) and Glenmark dated May 22, 2018 (the “Agreement”);
EXPLANATORY NOTE: [***] INDICATES THE PORTION OF THIS EXHIBIT THAT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL ANDLicense, Supply and Distribution Agreement • February 10th, 2020 • Elite Pharmaceuticals Inc /Nv/ • Pharmaceutical preparations
This Amendment, dated as of January 2, 2020 (the “Amendment”), by and between Elite Laboratories, Inc., a Delaware corporation, and Elite Pharmaceuticals, Inc., a Nevada corporation, with offices at 165 Ludlow Avenue, Northvale, New Jersey (“Elite”) and Glenmark Pharmaceuticals Inc. USA, a Delaware corporation located at 750 Corporate Drive, Mahwah, New Jersey 07430 (“Glenmark”) relating to that License, Supply and Distribution Agreement Between Elite and Glenmark dated May 22, 2018 and the Second Amendment to the License, Supply and Distribution Agreement dated August 1, 2018 (together the “Agreement”);
